2023-09-23 07:44:56
Title: Novo Nordisk Conducts Study to Determine Safety and Efficacy of Ozempic in Obese Children
Subtitle: Belgian hospitals participate in global research program targeting childhood obesity
Date: [Insert Date]
Brussels, Belgium – The Step Young research program, which aims to combat childhood obesity, is currently underway in university hospitals in Brussels, Leuven, and Antwerp. As participants, the hospitals will collaborate with the Danish pharmaceutical giant, Novo Nordisk, to assess the safety and effectiveness of semaglutide injections, the active substance of the weight loss drug Ozempic, in obese children aged between 6 to 12 years old. This was reported by De Tijd on Saturday.
Belgium is one of ten countries taking part in the trial, which involves 210 test subjects worldwide. The eligibility criteria require children to have a body mass index (BMI) above a certain threshold value.
Karolien Van De Maele, coordinator of the multidisciplinary obesity team at UZA (University Hospital Antwerp), expressed her satisfaction with the ongoing study. She stated, “In young people with a very high BMI, it is difficult to achieve sufficient results with exercise and diet alone.” Dr. Van De Maele believes that the ability to lose weight more rapidly with the help of semaglutide can provide extra motivation for obese children. Additionally, she sees potential long-term benefits, as she expects a decrease in the risk of diabetes and cardiovascular diseases among the participants.
The Step Young research program represents a crucial step forward in addressing the rising prevalence of childhood obesity. With the prevalence of obesity among children steadily increasing, experts emphasize the importance of preventive measures and effective treatment options. Through this global study, Novo Nordisk aims to contribute to the development of safe and effective weight loss treatments for children.
To ensure that the research findings are reliable and accurate, access to all functionalities of the study is reserved for professional healthcare providers. Healthcare professionals are encouraged to log in or register for free to gain full access to the content. Journalists or individuals wishing to provide information can reach out to the editorial team at [email protected].
As the Step Young research program progresses, it holds the promise of providing valuable insights that could potentially revolutionize the approach to childhood obesity treatment. The collaboration between Novo Nordisk and Belgian hospital institutions showcases the dedication and collective effort in addressing this pressing global health issue.]
#Belgian #children #test #injection #lose #weight